Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Dorota ŁażewskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0001-8454-4440
Maria KaletaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.
Paula ZarębaDepartment of Physicochemical Drug Analysis, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.
Justyna GodyńDepartment of Physicochemical Drug Analysis, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0002-0295-2772
Mariam DubielInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Düuesseldorf, Germany.ORCID 0000-0003-2055-4935
Ewelina Honkisz-OrzechowskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0002-2046-4879
Agata Doroz-PłonkaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.
Anna WięckowskaDepartment of Physicochemical Drug Analysis, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0003-2549-170X
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Düuesseldorf, Germany.ORCID 0000-0003-3336-1710
Katarzyna Kieć-KononowiczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0002-6752-7443
Funding
Deutsche Forschungsgemeinschaft GRK2158Jagiellonian University Medical College in Kraków N42/DBS/000300
6 · The paper itself
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder, for which there is no effective cure. Current drugs only slow down the course of the disease, and, therefore, there is an urgent need to find effective therapies that not only treat, but also prevent it. Acetylcholinesterase inhibitors (AChEIs), among others, have been used for years to treat AD. Histamine H
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Multitargeting Histamine H · full record | OpenQuestion